IVG-PREMIUM-E-LIQUIDS
25.3.2019 10:04:10 CET | Business Wire | Press release
IVG Premium E-Liquids, the UK’s market-leading brand, has announced a strategic partnership with globally renowned Kollaras & Co – A 3rd generation, family owned and operated business. Kollaras & Co specialises in supporting independent retailers across multiple channels in Australia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005029/en/
Kollaras & Co have landed the master distribution rights for IVG products within Australia, which will allow vapers from down under to join vapers from over 60 countries and 6 continents that vape premium British flavours from IVG.
John Kollaras, Managing Director of Kollaras & Co, commented that the alliance was an important step for the near 60-year-old business, commenting “We are thrilled to partner with IVG, as we continue to strive to provide a unique offering within our portfolio, and cement our position as a dynamic solutions provider.” Kollaras continued: “Quality, authenticity and passion are three key values which we look for in partners, and IVG is no exception to this.”
Ahsan Bawa, CEO of IVG, commented that “Our incredible journey continues here at IVG, our multi international and award winning brand continues to reach new heights. We are proud and honoured to welcome the Kollaras family into our own, and this strategic alliance will help in those efforts on delivering IVG to a store near you. We are thrilled to officially announce the partnership with Kolloras & Co, a key step for Oceania & South Pacific regions
Kollaras & Co will be distributing 26 delicious e-liquid flavours in 60 ML and 10 ML from IVG Premium E-Liquids’ into the Australia retail market sector by the end of April 2019.
13 International Accolades “Leading E-Liquids Specialist 2019”, Best Sweet Flavour, and more have played a key role in the Australia company taking the products on board, along with the existing reviews of the vape enthusiasts in the Australian market.
Kollaras closed by adding “Our core innovation metrics focus on creating brands that are valued by our customers and deliver outstanding value to their shoppers, and IVG is a fantastic example of this. We are both confident and excited about the partnership and our growth prospects in the year ahead to say the least!”
About IVG Premium E-Liquids - www.ivgeliquids.co.uk
About Kollaras & Co: www.kollaras.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005029/en/
Contact:
Media Contact: Deepika Patel Head of Marketing +44 (0) 1772 217000 deepika.patel@ivgeliquids.com
Social Media:
https://www.facebook.com/ivgeliquids
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom